Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954184 | 0.87 | P2RY12 (0.49) | KDM4EHSD17B10P2RY12GAAL3MBTL1 | |
| SCHEMBL719802 | 0.85 | TDP1 (0.50) | KDM4EHSD17B10P2RY12GAAL3MBTL1 | |
| SCHEMBL11194084 | 0.85 | P2RY12 (0.48) | KDM4EHSD17B10P2RY12GAAL3MBTL1 | |
| SCHEMBL14955100 | 0.85 | P2RY12 (0.48) | KDM4EHSD17B10P2RY12GAAL3MBTL1 | |
| SCHEMBL15582692 | 0.84 | GAA (0.49) | KDM4EP2RY12GAAL3MBTL1CYP2C9 | |
| SCHEMBL12467752 | 0.83 | L3MBTL1 (0.61) | KDM4EHSD17B10P2RY12GAAL3MBTL1 | |
| SCHEMBL3948173 | 0.81 | P2RY12 (0.45) | KDM4EHSD17B10P2RY12GAAL3MBTL1 | |
| SCHEMBL2121810 | 0.80 | P2RY12 (0.47) | KDM4EHSD17B10P2RY12GAAL3MBTL1 | |
| SCHEMBL16659359 | 0.79 | KDM4E (0.46) | KDM4EGAAALDH1A1HPGDPOLB | |
| SCHEMBL2227107 | 0.79 | XDH (0.49) | KDM4EHSD17B10ALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2022178256-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-111825654-A | Phenylmethylene piperidine derivatives, preparation method, intermediates and uses thereof | 北京酷瓴生物技术有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211836-A1 | BENZENE PIPERIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | 北京酷瓴生物技术有限公司 | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211836-A1 | BENZENE PIPERIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | 北京酷瓴生物技术有限公司 | 2020-10-22 | — | — | WO | disclosed |
| CN-107001342-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-106536489-B | Retinoid-related orphan receptor gamma modulators and uses thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-10188653-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3148987-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-3148987-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | KDM4E 3183/4885HSD17B10 2907/4885P2RY12 253/4885 |
| US-10188653-B2 | Diacylglycerol acyltransferase 2 inhibitors | DGAT2, LCLAT1, DGAT1 | KDM4E 3061/4885HSD17B10 403/4885P2RY12 4628/4885 |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | GPR119, FABP4, SULT2A1 | KDM4E 2527/4885HSD17B10 134/4885P2RY12 145/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | KDM4E 2959/4885HSD17B10 2733/4885P2RY12 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.